Canaccord initiated coverage of MapLight Therapeutics (MPLT) with a Buy rating and $35 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds